Jefferies Financial Group Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Research analysts at Jefferies Financial Group started coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Tuesday, Briefing.com reports. The firm set a “buy” rating on the stock.

Other research analysts have also issued research reports about the company. Scotiabank assumed coverage on Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They issued an “overweight” rating on the stock. Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics has a consensus rating of “Buy” and an average price target of $89.11.

Keros Therapeutics Trading Up 4.0 %

NASDAQ KROS traded up $2.39 during trading on Tuesday, reaching $62.34. The company’s stock had a trading volume of 152,207 shares, compared to its average volume of 367,771. The stock has a market capitalization of $2.34 billion, a PE ratio of -11.96 and a beta of 1.23. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The business has a 50-day moving average price of $56.53 and a 200-day moving average price of $51.86.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The business had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the previous year, the firm posted ($1.27) earnings per share. As a group, analysts expect that Keros Therapeutics will post -4.9 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its position in Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after purchasing an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics in the 2nd quarter valued at $1,118,000. Bank of New York Mellon Corp grew its position in Keros Therapeutics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after acquiring an additional 18,755 shares during the period. Swiss National Bank raised its stake in Keros Therapeutics by 22.0% during the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $3,303,000 after acquiring an additional 9,000 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Keros Therapeutics during the second quarter valued at $532,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.